Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Thrombocytopenia 2Hemorrhage 2Postoperative Hemorrhage 1Pituitary Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Breast Neoplasms 1

Interventions

pasireotide 4Temozolomide 2lutetium Lu 177 dotatate 1farletuzumab 1antineoplaston AS 2-1 1antineoplaston A10 1Tranexamic Acid 1Thyrotropin-Releasing Hormone 1TBR-760 1Rosiglitazone 1Nivolumab 1Microarray Analysis 1Lapatinib 1Ipilimumab 1DNA Methylation 1Complementary Therapies 1Capecitabine 1Cabergoline 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Pituitary Neoplasms × Tranexamic Acid × Clear all
NCT04863339 2022-04-05

Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery

University of North Carolina, Chapel Hill

Phase 2 Withdrawn
Endocrine

Hemorrhage, Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡